Literature DB >> 27296828

Overuse of short-acting beta-agonist bronchodilators in COPD during periods of clinical stability.

Vincent S Fan1, Ina Gylys-Colwell2, Emily Locke2, Kaharu Sumino3, Huong Q Nguyen4, Rachel M Thomas2, Sheryl Magzamen5.   

Abstract

BACKGROUND: Overuse of short-acting beta-agonists (SABA) is described in asthma, but little is known about overuse of SABA in chronic obstructive pulmonary disease (COPD).
METHODS: Prospective 3-month cohort study of patients with moderate-to-severe COPD who were provided a portable electronic inhaler sensor to monitor daily SABA use. Subjects wore a pedometer for 3 seven-day periods and were asked to complete a daily diary of symptoms and inhaler use. Overuse was defined as >8 actuations of their SABA per day while clinically stable.
RESULTS: Among 32 participants, 15 overused their SABA inhaler at least once (mean 8.6 ± 5.0 puffs/day), and 6 overused their inhaler more than 50% of monitored days. Compared to those with no overuse, overusers had greater dyspnea (modified Medical Research Council Dyspnea Scale: 2.7 vs. 1.9, p = 0.02), were more likely to use home oxygen (67% vs. 29%, p = 0.04), and were more likely to be on maximal inhaled therapy (long-acting beta-agonist, long-acting antimuscarinic agent, and an inhaled steroid: 40% vs. 6%, p = 0.03), and most had completed pulmonary rehabilitation (67% vs. 0%, p < 0.001). However, 27% of overusers of SABA were not on guideline-concordant COPD therapy.
CONCLUSIONS: Overuse of SABA was common and associated with increased disease severity and symptoms, even though overusers were on more COPD-related inhalers and more had completed pulmonary rehabilitation. More research is needed to understand factors associated with inhaler overuse and how to improve correct inhaler use. Published by Elsevier Ltd.

Entities:  

Keywords:  Adherence; Adrenergic beta-2 receptor agonists; Medication; Metered dose inhaler; Pulmonary disease, chronic obstructive; Telemedicine

Mesh:

Substances:

Year:  2016        PMID: 27296828     DOI: 10.1016/j.rmed.2016.05.011

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  10 in total

1.  Pilot Study of a Patient Experience with an ELLIPTA Inhaler Electronic Medication Monitor and Associated Integrated System: A Prospective Observational Study Using the COPD Patient-Powered Research Network.

Authors:  Barbara P Yawn; Gretchen M McCreary; John A Linnell; Cara B Pasquale; Elisha Malanga; Radmila Choate; David A Stempel; Rahul Gondalia; Leanne Kaye; Kathryn A Collison; Benjamin S Wu; Daniel Gratie; Richard H Stanford; Ryan Tomlinson
Journal:  Chronic Obstr Pulm Dis       Date:  2021-10-28

Review 2.  Digital Inhalers for Asthma or Chronic Obstructive Pulmonary Disease: A Scientific Perspective.

Authors:  Amy H Y Chan; Roy A Pleasants; Rajiv Dhand; Stephen L Tilley; Stephen A Schworer; Richard W Costello; Rajan Merchant
Journal:  Pulm Ther       Date:  2021-08-11

3.  Do not do in COPD: consensus statement on overuse.

Authors:  Felipe Villar-Álvarez; Raúl Moreno-Zabaleta; Jose Joaquin Mira-Solves; Eduardo Calvo-Corbella; Salvador Díaz-Lobato; Fernando González-Torralba; Ascensión Hernando-Sanz; Sara Núñez-Palomo; Sergio Salgado-Aranda; Beatriz Simón-Rodríguez; Paz Vaquero-Lozano; Isabel María Navarro-Soler
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-02-02

4.  Effect of Bronchodilator and Steroid Use on Heart Disease and Stroke Risks in a Bronchiectasis-Chronic Obstructive Pulmonary Disease Overlap Cohort: A Propensity Score Matching Study.

Authors:  Jun-Jun Yeh; Yu-Cih Yang; Chung Y Hsu; Chia-Hung Kao
Journal:  Front Pharmacol       Date:  2019-11-27       Impact factor: 5.810

5.  Passive Monitoring of Short-Acting Beta-Agonist Use via Digital Platform in Patients With Chronic Obstructive Pulmonary Disease: Quality Improvement Retrospective Analysis.

Authors:  Jessica Chen; Leanne Kaye; Michael Tuffli; Meredith A Barrett; Shelanda Jones-Ford; Tina Shenouda; Rahul Gondalia; Kelly Henderson; Veronica Combs; David Van Sickle; David A Stempel
Journal:  JMIR Form Res       Date:  2019-10-23

6.  Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany.

Authors:  Heinrich Worth; Carl-Peter Criée; Claus F Vogelmeier; Peter Kardos; Eva-Maria Becker; Karel Kostev; Ingo Mokros; Andrea Schneider
Journal:  Respir Res       Date:  2021-04-16

Review 7.  Inhaled Drug Therapy-Associated Adverse Reactions in Obstructive Respiratory Diseases: A Review of a Decade of Reporting to the Portuguese Pharmacovigilance System.

Authors:  Willy Fonseca; Cristina Monteiro; Luís Taborda-Barata
Journal:  Int J Environ Res Public Health       Date:  2021-11-25       Impact factor: 3.390

Review 8.  Potential cellular endocrinology mechanisms underlying the effects of Chinese herbal medicine therapy on asthma.

Authors:  Zeyu Meng; Huize Chen; Chujun Deng; Shengxi Meng
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-16       Impact factor: 6.055

9.  Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy.

Authors:  Chad Moretz; Ashley L Cole; George Mu; Benjamin Wu; Amy Guisinger; Yunhao Liu; Beth Hahn; Lee Baylis
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-09-16

10.  Reducing carbon footprint of inhalers: analysis of climate and clinical implications of different scenarios in five European countries.

Authors:  Daniele Pernigotti; Carol Stonham; Sara Panigone; Federica Sandri; Rossella Ferri; Yasemin Unal; Nicolas Roche
Journal:  BMJ Open Respir Res       Date:  2021-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.